These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 15050146

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.
    Magliocca JF, Knechtle SJ.
    Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530
    [Abstract] [Full Text] [Related]

  • 24. Results of intestinal and multivisceral transplantation in adult patients: Italian experience.
    Lauro A, Dazzi A, Ercolani G, Cescon M, D'Errico A, Di Simone M, Grazi GL, Vivarelli M, Varotti G, De Ruvo N, Masetti M, Cautero N, Di Benedetto F, Siniscalchi A, Begliomini B, Lazzarotto T, Faenza S, Pironi L, Pinna AD.
    Transplant Proc; 2006 Sep; 38(6):1696-8. PubMed ID: 16908252
    [Abstract] [Full Text] [Related]

  • 25. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.
    Yuan-Xin L, Ning L, You-Sheng L, Xiao-Dong N, Ming L, Jian W, Jie-Shou L.
    Transplant Proc; 2010 Sep; 42(1):29-34. PubMed ID: 20172275
    [Abstract] [Full Text] [Related]

  • 26. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.
    Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, Fernandez LA, Thomas Chin L, Becker YT, Odorico JS, D'Alessandro AM, Sollinger HW, Knechtle SJ.
    Transpl Int; 2006 Nov; 19(11):885-92. PubMed ID: 17018123
    [Abstract] [Full Text] [Related]

  • 27. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
    Shah AJ, Kapoor N, Crooks GM, Weinberg KI, Azim HA, Killen R, Kuo L, Rushing T, Kohn DB, Parkman R.
    Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
    [Abstract] [Full Text] [Related]

  • 28. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
    Basu A, Ramkumar M, Tan HP, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.
    Transplant Proc; 2005 Mar; 37(2):923-6. PubMed ID: 15848576
    [Abstract] [Full Text] [Related]

  • 29. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
    Baez Y, Giron F, Niño-Murcia A, Rodríguez J, Salcedo S.
    Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
    [Abstract] [Full Text] [Related]

  • 30. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
    Bond GJ, Mazariegos GV, Sindhi R, Abu-Elmagd KM, Reyes J.
    J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
    [Abstract] [Full Text] [Related]

  • 31. Intestinal transplantation: advances in immunosuppression and surgical techniques.
    Tzakis AG, Tryphonopoulos P, Kato T, Nishida S, Levi DM, Nery JR, Madariaga J, De Faria W, Mittal N, Thompson JF, Ruiz P.
    Transplant Proc; 2003 Aug; 35(5):1925-6. PubMed ID: 12962850
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance.
    Abu-Elmagd KM, Costa G, Bond GJ, Wu T, Murase N, Zeevi A, Simmons R, Soltys K, Sindhi R, Stein W, Demetris A, Mazariegos G.
    Transpl Int; 2009 Jan; 22(1):96-109. PubMed ID: 18954362
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Analysis of rejection episodes in over 100 pediatric intestinal transplant recipients.
    Selvaggi G, Kato T, Gaynor JJ, Thompson J, Nishida S, Madariaga J, Levi D, Moon J, Ruiz P, Cantwell P, Tuteja S, Tzakis A.
    Transplant Proc; 2006 Jan; 38(6):1711-2. PubMed ID: 16908257
    [Abstract] [Full Text] [Related]

  • 36. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
    Burton CM, Andersen CB, Jensen AS, Iversen M, Milman N, Boesgaard S, Arendrup H, Eliasen K, Carlsen J.
    J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Expanded use of multivisceral transplantation for small children with concurrent liver and intestinal failure.
    Kato T, Selvaggi G, Gaynor J, Madariaga J, McLaughlin G, Thompson J, Nishida S, Moon J, Levi D, Ruiz P, Tzakis A.
    Transplant Proc; 2006 Jun; 38(6):1705-8. PubMed ID: 16908255
    [Abstract] [Full Text] [Related]

  • 40. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.
    Ekberg H, Bäckman L, Tufveson G, Tydén G.
    Transplant Proc; 1999 Jun; 31(1-2):267-8. PubMed ID: 10083102
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.